Maria Donata Di Taranto

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2690975/maria-donata-di-taranto-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36 15 529 22 h-index g-index citations papers 688 3.67 41 3.4 avg, IF L-index ext. papers ext. citations

#	Paper	IF	Citations
36	Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 ,	4.5	1
35	Targeting Nanostrategies for Imaging of Atherosclerosis. <i>Contrast Media and Molecular Imaging</i> , 2021 , 2021, 6664471	3.2	4
34	A case of Cerebrotendinous Xanthomatosis with spinal cord involvement and without tendon xanthomas: identification of a new mutation of the CYP27A1 gene. <i>Acta Neurologica Belgica</i> , 2021 , 121, 561-566	1.5	3
33	Correlation between low adenosine A receptor expression and hypercholesterolemia: A new component of the cardiovascular risk?. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021 , 1866, 158850	5	2
32	The Role of Immunosuppressive Therapy in Aneurysmal Degeneration of Hemodialysis Fistulas in Renal Transplant Patients. <i>Annals of Vascular Surgery</i> , 2021 , 74, 21-28	1.7	1
31	The Impact of Chronic Kidney Disease on Peripheral Artery Disease and Peripheral Revascularization. <i>International Journal of General Medicine</i> , 2021 , 14, 3749-3759	2.3	О
30	Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement. <i>Clinical Genetics</i> , 2021 , 100, 529-541	4	2
29	Galectin-3 in Cardiovascular Diseases. International Journal of Molecular Sciences, 2020, 21,	6.3	17
28	Changes in carotid stiffness in patients with familial hypercholesterolemia treated with Evolocumab□: A prospective cohort study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 996-1004	4.5	9
27	A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
26	Lipoprotein (a) is an independent predictor of cardiovascular events in Mediterranean women (Progetto Atena). European Journal of Preventive Cardiology, 2020 , 27, 2248-2250	3.9	3
25	Familial hypercholesterolemia: A complex genetic disease with variable phenotypes. <i>European Journal of Medical Genetics</i> , 2020 , 63, 103831	2.6	26
24	Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy. <i>Thrombosis Research</i> , 2020 , 194, 229-2	36 ^{8.2}	13
23	Endovascular Treatment versus Medical Therapy for Hypertensive Patients with Renal Artery Stenosis: An Updated Systematic Review. <i>Annals of Vascular Surgery</i> , 2019 , 61, 445-454	1.7	7
22	Lipid profile and genetic status in a familial hypercholesterolemia pediatric population: exploring the LDL/HDL ratio. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1102-1110	5.9	7
21	The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9. <i>Atherosclerosis</i> , 2019 , 289, 162-172	3.1	12
20	Age-related changes of cholestanol and lathosterol plasma concentrations: an explorative study. <i>Lipids in Health and Disease</i> , 2019 , 18, 235	4.4	5

(2008-2018)

19	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. <i>Atherosclerosis</i> , 2018 , 277, 413-418	3.1	35	
18	Characterization of two novel pathogenic variants at compound heterozygous status in lipase maturation factor 1 gene causing severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 1253-1259	4.9	4	
17	Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1051-1059	3.9	17	
16	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). <i>Atherosclerosis Supplements</i> , 2017 , 29, 11-16	1.7	38	
15	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017 , 29, 17-24	1.7	45	
14	Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia. <i>Scientific Reports</i> , 2017 , 7, 15282	4.9	24	
13	Cerebrotendinous xanthomatosis, a metabolic disease with different neurological signs: two case reports. <i>Metabolic Brain Disease</i> , 2016 , 31, 1185-8	3.9	14	
12	Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: integration and evolution of genetic diagnosis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015 , 25, 979-87	4.5	23	
11	Association of USF1 and APOA5 polymorphisms with familial combined hyperlipidemia in an Italian population. <i>Molecular and Cellular Probes</i> , 2015 , 29, 19-24	3.3	28	
10	Statistical and Computational Methods for Genetic Diseases: An Overview. <i>Computational and Mathematical Methods in Medicine</i> , 2015 , 2015, 954598	2.8	12	
9	The novel variant p.Ser465Leu in the PCSK9 gene does not account for the decreased LDLR activity in members of a FH family. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014 , 52, e175-8	5.9	16	
8	Investigation of Single Nucleotide Polymorphisms Associated to Familial Combined Hyperlipidemia with Random Forests. <i>Smart Innovation, Systems and Technologies</i> , 2013 , 169-178	0.5	12	
7	Altered expression of inflammation-related genes in human carotid atherosclerotic plaques. <i>Atherosclerosis</i> , 2012 , 220, 93-101	3.1	26	
6	An improved method on stimulated T-lymphocytes to functionally characterize novel and known LDLR mutations. <i>Journal of Lipid Research</i> , 2011 , 52, 2095-100	6.3	17	
5	C-reactive protein levels are associated with paraoxonase polymorphism L55M in patients undergoing cardiac SPECT imaging. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011 , 71, 179-84	2	4	
4	Identification and functional characterization of LDLR mutations in familial hypercholesterolemia patients from Southern Italy. <i>Atherosclerosis</i> , 2010 , 210, 493-6	3.1	26	
3	Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study. <i>Liver International</i> , 2009 , 29, 248-52	7.9	24	
2	Decreased paraoxonase-2 expression in human carotids during the progression of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 594-600	9.4	31	

Polymorphisms and the expression of genes encoding enzymes involved in cardiovascular diseases. Clinica Chimica Acta, **2007**, 381, 21-5

6.2 11